Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

F. Efficace, F. Stagno, A. Iurlo, M. Breccia, F. Cottone, M. Bonifacio, E. Abruzzese, F. Castagnetti, G. Caocci, M. Crugnola, I. Capodanno, B. Martino, M. Tiribelli, A. Patriarca, A. Gozzini, P. Pregno, S. Saussele, N. Cascavilla, C. Fozza, M. BergamaschiG. Binotto, M. Vignetti, G. Rosti

Research output: Contribution to journalArticle

Abstract

There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
Original languageEnglish
JournalLeukemia
DOIs
Publication statusPublished - 2019

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quality of Life
Confidence Intervals
Protein-Tyrosine Kinases
Therapeutics
Licensure
Imatinib Mesylate
Dasatinib
Case-Control Studies
Age Groups
Safety
Neoplasms

Cite this

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. / Efficace, F.; Stagno, F.; Iurlo, A.; Breccia, M.; Cottone, F.; Bonifacio, M.; Abruzzese, E.; Castagnetti, F.; Caocci, G.; Crugnola, M.; Capodanno, I.; Martino, B.; Tiribelli, M.; Patriarca, A.; Gozzini, A.; Pregno, P.; Saussele, S.; Cascavilla, N.; Fozza, C.; Bergamaschi, M.; Binotto, G.; Vignetti, M.; Rosti, G.

In: Leukemia, 2019.

Research output: Contribution to journalArticle

Efficace, F, Stagno, F, Iurlo, A, Breccia, M, Cottone, F, Bonifacio, M, Abruzzese, E, Castagnetti, F, Caocci, G, Crugnola, M, Capodanno, I, Martino, B, Tiribelli, M, Patriarca, A, Gozzini, A, Pregno, P, Saussele, S, Cascavilla, N, Fozza, C, Bergamaschi, M, Binotto, G, Vignetti, M & Rosti, G 2019, 'Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy', Leukemia. https://doi.org/10.1038/s41375-019-0563-0
Efficace, F. ; Stagno, F. ; Iurlo, A. ; Breccia, M. ; Cottone, F. ; Bonifacio, M. ; Abruzzese, E. ; Castagnetti, F. ; Caocci, G. ; Crugnola, M. ; Capodanno, I. ; Martino, B. ; Tiribelli, M. ; Patriarca, A. ; Gozzini, A. ; Pregno, P. ; Saussele, S. ; Cascavilla, N. ; Fozza, C. ; Bergamaschi, M. ; Binotto, G. ; Vignetti, M. ; Rosti, G. / Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. In: Leukemia. 2019.
@article{740322cfee434662a1cb4a8a747a197c,
title = "Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy",
abstract = "There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95{\%} confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95{\%} CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95{\%} CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions. {\circledC} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",
author = "F. Efficace and F. Stagno and A. Iurlo and M. Breccia and F. Cottone and M. Bonifacio and E. Abruzzese and F. Castagnetti and G. Caocci and M. Crugnola and I. Capodanno and B. Martino and M. Tiribelli and A. Patriarca and A. Gozzini and P. Pregno and S. Saussele and N. Cascavilla and C. Fozza and M. Bergamaschi and G. Binotto and M. Vignetti and G. Rosti",
note = "Export Date: 23 September 2019",
year = "2019",
doi = "10.1038/s41375-019-0563-0",
language = "English",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

AU - Efficace, F.

AU - Stagno, F.

AU - Iurlo, A.

AU - Breccia, M.

AU - Cottone, F.

AU - Bonifacio, M.

AU - Abruzzese, E.

AU - Castagnetti, F.

AU - Caocci, G.

AU - Crugnola, M.

AU - Capodanno, I.

AU - Martino, B.

AU - Tiribelli, M.

AU - Patriarca, A.

AU - Gozzini, A.

AU - Pregno, P.

AU - Saussele, S.

AU - Cascavilla, N.

AU - Fozza, C.

AU - Bergamaschi, M.

AU - Binotto, G.

AU - Vignetti, M.

AU - Rosti, G.

N1 - Export Date: 23 September 2019

PY - 2019

Y1 - 2019

N2 - There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.

AB - There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17–14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82–21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42–11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.

U2 - 10.1038/s41375-019-0563-0

DO - 10.1038/s41375-019-0563-0

M3 - Article

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -